Source - RNS
RNS Number : 4145K
SOTIO a.s.
10 April 2018

Press Release

SOTIO to Present Translational Data of the IL-15 Superagonist
SO-C101 at 2018 AACR Annual Meeting


Prague, 10 April 2018

SOTIO, a biotechnology company owned by the PPF Group, announces today presentation  of a poster on SO-C101 at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2018. The poster, titled "Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response," will highlight preclinical and translational data evaluating SO-C101 (RLI-15). The AACR Annual Meeting will be held on April 14 - 18, 2018 in Chicago, Illinois. 

The poster will be presented at poster session PO.IM02.07 - Immunomodulatory Agents and Interventions 1 on April 17, 2018 at 8:00 a.m. - 12:00 p.m. An abstract of the presentation is available on AACR website.

The preclinical data show several positive effects of SO-C101 in the induction of anti-tumor immunity, including the combination treatment of SO-C101 with an anti-PD1 antibody leading to a significant anti-tumor efficacy in a TRAMP-C2 prostate cancer mouse model with 70% of mice remaining tumor free after the treatment. The activity of clinical-grade SO-C101 was tested in vitro on human PBMCs and the superiority over IL-2 and IL-15 stimulatory capacity has been confirmed. Furthermore, SO-C101 induced lymphocyte activation and expansion in non-human primates at well tolerated doses.

About SO-C101:

SO-C101 is developed in collaboration with Cytune Pharma, an affiliated company of SOTIO. SO-C101 (RLI-15) is a human fusion protein of IL-15 and the high-affinity binding domain of IL-15Rα. It is a novel immunotherapeutic approach with potential applications in a variety of oncology indications. In preclinical experiments, SO-C101 has been shown to stimulate and induce proliferation of immune effector cells, such as cytotoxic T cells and NK cells, but it does not stimulate the immune-inhibitory regulatory T cells. Based on the preclinical experiments, SO-C101 is more potent and better tolerated compared to the unmodified IL-15 or IL-2. SO-C101 and other products based on this platform allow for combinations with other immunotherapeutic strategies including checkpoint inhibitors. SOTIO is planning to initiate a first in human study early in 2019.

For further information please contact:

Richard Kapsa

Head of Communication

T: (+420) 224 174 448

M: (+420) 603 280 971

[email protected] 



SOTIO is an international biotechnology company leading the efforts of PPF Group to build a diverse biotechnology portfolio through its own research & development, collaborations, in-licensing, investments, mergers and acquisitions. The company is developing new medical therapies, focusing on the treatment of cancer and autoimmune diseases. The most advanced project is the SOTIO proprietary platform of active cellular immunotherapy (ACI) based on dendritic cells. SOTIO is conducting multiple Phase I to Phase III clinical trials verifying the safety and efficacy of its DCVAC products. SOTIO is also collaborating with NBE Therapeutics on the development of novel antibody-drug conjugate products (ADC), with Cytune Pharma on developing novel IL15-based immunotherapies for the treatment of cancer and with LDC and the Max Planck Society on an oncology program addressing a novel target in tumor metabolism. SOTIO has facilities in Europe, the United States, China and Russia. For more information about the company visit the website

SOTIO is a registered trademark of SOTIO a.s. in selected countries.


This information is provided by RNS
The company news service from the London Stock Exchange